BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue

January 8, 2024

https://www.prnewswire.com/news-releases/biolife-solutions-announces-preliminary-fourth-quarter-and-full-year-2023-unaudited-revenue-302028158.html

Fourth quarter Cell Processing revenue increased 11% sequentially to $14.8 million

BOTHELL, Wash., Jan. 8, 2024 /PRNewswire/ — BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced 2023 fourth quarter and full year preliminary unaudited revenue.

Read more at prnewswire.com

Related news for (BLFS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.